Global Antiphospholipid Syndrome Score

Savino Sciascia; Munther Khamashta; Dario Roccatello

doi:10.1016/B978-0-444-63655-3.00014-4

Global Antiphospholipid Syndrome Score

Savino Sciascia, Munther Khamashta, Dario Roccatello

Women & Children's Health

S. Giovanni Bosco Hospital

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

Abstract

Early preventative strategies and possible treatment for individuals who are at high risk of developing an adverse outcome over a specific time is a main cornerstone of clinical research. From this perspective, we recently developed a risk score for antiphospholipid syndrome (APS), known as the Global APS Score (GAPSS). GAPSS takes into account the combination of independent risk factors for thrombosis and pregnancy loss, computing together the antiphospholipid antibodies (aPL) profile (criteria and noncriteria aPL), the conventional cardiovascular risk factors, and the autoimmune antibodies profile. Assessing the risk profile in patients with aPL is an unmet need, and recent evidence showed that GAPSS can be a useful tool to quantify the likelihood of developing APS-related clinical manifestations.

Original language	English
Title of host publication	Handbook of Systemic Autoimmune Diseases
Publisher	Elsevier Science Ltd
Pages	215-219
Number of pages	5
Volume	12
DOIs	https://doi.org/10.1016/B978-0-444-63655-3.00014-4
Publication status	Published - 2016

Publication series

Name	Handbook of Systemic Autoimmune Diseases
Volume	12
ISSN (Print)	15715078

Keywords

Antiphospholipid antibodies
Hughes syndrome
pregnancy loss
thrombosis

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/B978-0-444-63655-3.00014-4

Cite this

@inbook{d737123290064d6e82812b39d4479d37,

title = "Global Antiphospholipid Syndrome Score",

abstract = "Early preventative strategies and possible treatment for individuals who are at high risk of developing an adverse outcome over a specific time is a main cornerstone of clinical research. From this perspective, we recently developed a risk score for antiphospholipid syndrome (APS), known as the Global APS Score (GAPSS). GAPSS takes into account the combination of independent risk factors for thrombosis and pregnancy loss, computing together the antiphospholipid antibodies (aPL) profile (criteria and noncriteria aPL), the conventional cardiovascular risk factors, and the autoimmune antibodies profile. Assessing the risk profile in patients with aPL is an unmet need, and recent evidence showed that GAPSS can be a useful tool to quantify the likelihood of developing APS-related clinical manifestations.",

keywords = "Antiphospholipid antibodies, Hughes syndrome, pregnancy loss, thrombosis",

author = "Savino Sciascia and Munther Khamashta and Dario Roccatello",

year = "2016",

doi = "10.1016/B978-0-444-63655-3.00014-4",

language = "English",

volume = "12",

series = "Handbook of Systemic Autoimmune Diseases",

publisher = "Elsevier Science Ltd",

pages = "215--219",

booktitle = "Handbook of Systemic Autoimmune Diseases",

}

TY - CHAP

T1 - Global Antiphospholipid Syndrome Score

AU - Sciascia, Savino

AU - Khamashta, Munther

AU - Roccatello, Dario

PY - 2016

Y1 - 2016

N2 - Early preventative strategies and possible treatment for individuals who are at high risk of developing an adverse outcome over a specific time is a main cornerstone of clinical research. From this perspective, we recently developed a risk score for antiphospholipid syndrome (APS), known as the Global APS Score (GAPSS). GAPSS takes into account the combination of independent risk factors for thrombosis and pregnancy loss, computing together the antiphospholipid antibodies (aPL) profile (criteria and noncriteria aPL), the conventional cardiovascular risk factors, and the autoimmune antibodies profile. Assessing the risk profile in patients with aPL is an unmet need, and recent evidence showed that GAPSS can be a useful tool to quantify the likelihood of developing APS-related clinical manifestations.

AB - Early preventative strategies and possible treatment for individuals who are at high risk of developing an adverse outcome over a specific time is a main cornerstone of clinical research. From this perspective, we recently developed a risk score for antiphospholipid syndrome (APS), known as the Global APS Score (GAPSS). GAPSS takes into account the combination of independent risk factors for thrombosis and pregnancy loss, computing together the antiphospholipid antibodies (aPL) profile (criteria and noncriteria aPL), the conventional cardiovascular risk factors, and the autoimmune antibodies profile. Assessing the risk profile in patients with aPL is an unmet need, and recent evidence showed that GAPSS can be a useful tool to quantify the likelihood of developing APS-related clinical manifestations.

KW - Antiphospholipid antibodies

KW - Hughes syndrome

KW - pregnancy loss

KW - thrombosis

UR - http://www.scopus.com/inward/record.url?scp=85016762392&partnerID=8YFLogxK

U2 - 10.1016/B978-0-444-63655-3.00014-4

DO - 10.1016/B978-0-444-63655-3.00014-4

M3 - Chapter

VL - 12

T3 - Handbook of Systemic Autoimmune Diseases

SP - 215

EP - 219

BT - Handbook of Systemic Autoimmune Diseases

PB - Elsevier Science Ltd

ER -

Global Antiphospholipid Syndrome Score

Abstract

Publication series

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this